Tag archive for ‘Cryoport sales from launch of Kymriah and Yescarta’
Cryoport: Updated Sales and Earnings Model (CYRX, Buy, $9.69)
Purpose of this Report With the commercial launches of the CAR-T products Kymriah and Yescarta, I am expecting a significant upward inflection in sales for Cryoport. The primary objective of this report is to formulate an improved sales and earnings model in order to show this. First quarter results from Cryoport, Novartis and Gilead have […]